Drug Profile
Research programme: monoclonal antibody therapeutics - Eisai Inc/University Hospital Heidelberg
Latest Information Update: 23 Jan 2020
Price :
$50
*
At a glance
- Originator Morphotek; University Hospital Heidelberg
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 15 Jan 2009 Early research in Cancer in Germany (Parenteral)